How long does Flualprazolam last?

The total duration of Flualprazolam via oral is 5 hours to 8 hours. Onset typically occurs within 20 minutes to 40 minutes. Peak effects last 1 hour to 2 hours.

Flualprazolam — SubstanceWiki

Flualprazolam

Benzodiazepines · Depressant

27 dangerous interactions — combining Flualprazolam with certain substances may be life-threatening.

See all

Depressant(Benzodiazepines)

Quick Dosage

oral0.3–0.5 mg (common)

Total duration (oral)5hr–8hr

View full details

Flualprazolam is a designer benzodiazepine and triazolobenzodiazepine, structurally related to alprazolam (Xanax) through the addition of a fluorine atom at the 2' position of the phenyl ring. It is substantially more potent and longer-acting than alprazolam, producing pronounced sedation, anxiolysis, muscle relaxation, and amnesia with an estimated duration of 12–24 hours from a single dose and active metabolites that can persist for several days. It emerged in the research chemical market around 2017 and generated significant community discussion — reflected in 12 Reddit posts in the database — due to its unexpectedly long duration, potency, and multiple reports of dangerous outcomes.

Community accounts on Reddit present a strikingly consistent picture of flualprazolam as deceptive in its duration and potency. Multiple posts describe users who found it "felt nothing like Xanax," either because effects built more gradually, lasted far longer, or produced qualitative characteristics — particularly pronounced sedation, next-day impairment, and amnesia — that distinguished it from the parent compound. The "afterglow" reported by some users represents one facet of this extended duration; the blackouts, unintentional impairment extending into the following day, and accumulation effects with repeated use represent the harm reduction concern.

The combination of triazolobenzodiazepine potency, long duration, and long-acting metabolites makes flualprazolam one of the most pharmacologically treacherous compounds in the designer benzodiazepine class. The inability to accurately predict its effective duration — even by experienced benzodiazepine users — has been a recurring theme in community accounts. It should be approached with extreme caution, and its use on consecutive days should be avoided entirely due to accumulation risk.

How It Feels

Flualprazolam announces itself with a speed and force that catches many off guard. Within fifteen to twenty minutes, a heavy wave of sedation descends, as though someone had draped a lead-lined curtain over consciousness. The anxiety does not fade; it is snuffed out, extinguished with a thoroughness that leaves behind a blank, warm void where worry used to live. The muscles go slack almost immediately, and the body sinks into whatever surface is available with the boneless surrender of a dropped marionette.

The come-up intensifies rapidly. The sedation deepens into a thick, narcotic fog that makes the world seem distant and slightly unreal. Speech begins to slur, words becoming soft and imprecise, as though the mouth has forgotten the exact mechanics of language. There is a euphoria present, but it exists beneath the sedation like a warm current beneath still water -- pleasant but difficult to fully appreciate through the growing haze. Motor coordination deteriorates noticeably: walking becomes a careful negotiation, and fine motor tasks are abandoned. There is a pronounced disinhibition that can lead to decisions that would be unthinkable in a sober state, delivered with a confidence that the impaired judgment cannot critique.

At the peak, consciousness narrows to a tunnel. The world outside the immediate field of attention ceases to exist in any meaningful sense. Memory begins to fragment -- moments arrive and depart without leaving footprints, and the continuous narrative of experience breaks into disconnected snapshots. The body is so relaxed that it feels almost paralyzed, a warm, heavy mass that registers comfort but not much else. Time becomes meaningless, its passage unmarked and unnoticed. The emotional state is one of deep, uncritical contentment: everything is fine, everything has always been fine, and the concept of things being otherwise seems absurd and distant.

The comedown is measured in hours of heavy sleep rather than a gradual tapering of effects. You do not so much come down as wake up, often many hours later, with a thick grogginess that clings to consciousness like fog in a valley. The residual sedation can last well into the following day, and the gaps in memory may be extensive, leaving behind an unsettling patchwork of half-remembered moments and blank spaces.

Detection Methods

Standard Drug Panel Inclusion

Flualprazolam is NOT reliably detected on standard immunoassay drug panels. As a fluorinated analogue of alprazolam, it was designed with structural modifications that reduce cross-reactivity with the antibodies used in conventional benzodiazepine screening. Some immunoassay platforms may produce weak positive results at higher concentrations due to partial structural similarity to alprazolam, but detection rates are inconsistent and unreliable. False negatives are common, making standard panel results meaningless for ruling out flualprazolam use.

Urine Detection

Flualprazolam and its metabolites, including alpha-hydroxyflualprazolam and 4-hydroxyflualprazolam, are detectable in urine for approximately 2 to 5 days after a single dose. The parent compound undergoes hepatic metabolism via CYP3A4, producing hydroxylated metabolites that are subsequently glucuronidated. Reliable urine detection requires LC-MS/MS methods specifically validated for flualprazolam and its metabolites. Standard benzodiazepine immunoassay panels miss this compound in the majority of cases.

Blood and Serum Detection

Blood detection windows are 1 to 3 days. Active blood concentrations are in the low nanogram range, typically 1 to 20 ng/mL. Flualprazolam has a half-life estimated at 6 to 12 hours, similar to its parent compound alprazolam. Forensic blood analysis increasingly includes flualprazolam as part of comprehensive designer benzodiazepine panels.

Hair Follicle Detection

Hair analysis for flualprazolam is possible with LC-MS/MS but is not routinely performed. Detection windows extend to approximately 90 days. The compound incorporates into the hair matrix at rates comparable to other fluorinated benzodiazepines.

Confirmatory Methods

LC-MS/MS is the only reliable confirmatory method. The compound must be explicitly included in the analytical panel, as it will not appear on standard benzodiazepine confirmation panels that only target prescribed medications. Reference standards for flualprazolam and its metabolites are commercially available from forensic chemistry suppliers. Published methods achieve limits of detection below 0.5 ng/mL in both urine and blood.

Reagent Testing

Reagent testing cannot reliably identify flualprazolam. The Zimmermann reagent may produce a faint color change, but results are inconsistent at the low doses found in typical preparations. Fentanyl test strips should be used on all flualprazolam products obtained from unregulated sources, as contamination with fentanyl and its analogues has been documented in seized samples.

Interactions

Substance	Status	Note
Atropa belladonna	Dangerous	Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Cake	Dangerous	Combined CNS depression; risk of respiratory failure
Datura	Dangerous	Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Deschloroetizolam	Dangerous	Combined CNS depression; risk of respiratory failure
Desomorphine	Dangerous	Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Diclazepam	Dangerous	Combined CNS depression; risk of respiratory failure
Diphenhydramine	Dangerous	Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Dissociatives	Dangerous	—
Eszopiclone	Dangerous	Combined CNS depression; risk of respiratory failure
Etizolam	Dangerous	Combined CNS depression; risk of respiratory failure
Flubromazepam	Dangerous	Combined CNS depression; risk of respiratory failure
Flubromazolam	Dangerous	Combined CNS depression; risk of respiratory failure
Flunitrazepam	Dangerous	Combined CNS depression; risk of respiratory failure
Flunitrazolam	Dangerous	Combined CNS depression; risk of respiratory failure
Gaboxadol	Dangerous	Combined CNS depression; risk of respiratory failure
Harmala alkaloid	Dangerous	Unpredictable potentiation of CNS depression; risk of respiratory failure
Lorazepam	Dangerous	Combined CNS depression; risk of respiratory failure
Mephenaqualone	Dangerous	Combined CNS depression; risk of respiratory failure
Metizolam	Dangerous	Combined CNS depression; risk of respiratory failure
Midazolam	Dangerous	Combined CNS depression; risk of respiratory failure
Naloxone	Dangerous	Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Nicotine	Dangerous	Combined CNS depression; risk of respiratory failure
Nifoxipam	Dangerous	Combined CNS depression; risk of respiratory failure
Peganum harmala	Dangerous	Unpredictable potentiation of CNS depression; risk of respiratory failure
Pentobarbital	Dangerous	Combined CNS depression; risk of respiratory failure
Phenobarbital	Dangerous	Combined CNS depression; risk of respiratory failure
SAMe	Dangerous	Combined CNS depression; risk of respiratory failure
3-Cl-PCP	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
3-FMA	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
3-HO-PCE	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
3-HO-PCP	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
3-MeO-PCE	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
3-MeO-PCMo	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
3-MeO-PCP	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
4-MeO-PCP	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
4-MMC	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
8-Chlorotheophylline	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Adrafinil	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Anandamide	Caution	Increased sedation and cognitive impairment
APICA	Caution	Increased sedation and cognitive impairment
Benzydamine	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Bromantane	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Cannabidiol	Caution	Increased sedation and cognitive impairment
Deschloroketamine	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Dichloropane	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Diphenidine	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Ephedrine	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Ephenidine	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Hexedrone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
HXE	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Inhalants	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Memantine	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Methcathinone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
MXiPr	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
O-PCE	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Oxiracetam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
PCE	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Phenylpiracetam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Rhodiola Rosea	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Psilocybin Mushrooms	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers

Showing 60 key interactions out of 79 total.

Toxicity & Safety

Duration Deception

The most clinically significant toxicity concern with flualprazolam — repeatedly emphasized in community discourse — is that its actual pharmacological duration substantially exceeds user expectations based on onset and initial subjective experience. Effects begin building gradually, peak late, and persist long after users may believe they have resolved. This creates risk of:

Driving while impaired when subjectively feeling recovered
Redosing before the first dose has offset
Next-day sedation, amnesia, and impairment affecting work or academic performance
Cumulative accumulation with repeated dosing

Memory Effects and Blackout

Flualprazolam produces pronounced anterograde amnesia, with community reports of blackouts occurring at doses not perceived as extreme. The triazolo ring pharmacophore is associated with particularly strong amnestic properties (seen also in triazolam, marketed as Halcion and widely documented for blackout-related adverse events).

Physical Dependence and Withdrawal

Regular flualprazolam use produces physical dependence comparable to other high-potency triazolobenzodiazepines. The long half-life provides some buffering of withdrawal onset, but abrupt cessation after prolonged use can produce seizures. The potency means that even modest cumulative doses can establish significant physical dependence.

Respiratory Depression

Standard benzodiazepine respiratory depression risk applies. Combination with alcohol or opioids is particularly dangerous given the extended pharmacological duration — a user may not recognize that flualprazolam remains pharmacologically active when adding another CNS depressant hours after the dose.

No Clinical Data

No clinical trials exist establishing a safety profile or dose range. All dosing is based on community experience with inherent uncertainties.

Overdose Information

Depressant overdose from Flualprazolam is a life-threatening medical emergency. The primary mechanism of death is respiratory depression leading to respiratory arrest.

Signs of overdose: Extremely slow or stopped breathing, blue lips or fingertips (cyanosis), pinpoint pupils, unresponsiveness, cold/clammy skin, gurgling or snoring sounds (may indicate airway obstruction), very slow heart rate.

Emergency response:

Call emergency services immediately
If the person is not breathing, begin rescue breathing or CPR
Place unconscious but breathing person in the recovery position
Administer naloxone if opioid involvement is suspected
Stay with the person until help arrives
Be honest with emergency responders about all substances consumed

Critical combination risk: The combination of Flualprazolam with other depressants (alcohol, benzodiazepines, opioids) is the most common scenario for fatal depressant overdose. The respiratory depression from multiple depressants is synergistic (greater than the sum of individual effects).

Dangerous Interactions

The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.

Atropa belladonnaDangerous

Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure

CakeDangerous

Combined CNS depression; risk of respiratory failure

DaturaDangerous

Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure

DeschloroetizolamDangerous

Combined CNS depression; risk of respiratory failure

DesomorphineDangerous

Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths